NCT01657591 - Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2012

Primary Completion Date

September 20, 2016

Study Completion Date

September 21, 2021

Conditions

Melanoma

Interventions

DRUG

XL888

Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg

DRUG

Vemurafenib

Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa